The potential of lung epithelium specific proteins as biomarkers for covid-19-associated lung injury

Sultan Almuntashiri, Chelsea James, Xiaoyun Wang, Budder Siddiqui, Duo Zhang

Research output: Contribution to journalReview articlepeer-review

Abstract

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection was first reported in Wuhan, China, and was declared a pandemic by the World Health Organization (WHO) on 20 March 2020. The respiratory system is the major organ system affected by COVID-19. Numerous studies have found lung abnormalities in patients with COVID-19, including shortness of breath, respiratory failure, and acute respiratory distress syndrome. The identification of lung-specific biomarkers that are easily measurable in serum would be valuable for both clinicians and patients with such conditions. This review is focused on the pneumoproteins and their potential to serve as biomarkers for COVID-19-associated lung injury, including Krebs von den Lungen-6 (KL-6), surfactant proteins (SP-A, SP-B, SP-C, SP-D), and Clara cell secretory protein (CC16). The current findings indicate the aforementioned pneumoproteins may reflect the severity of pulmonary manifestations and could serve as potential biomarkers in COVID-19-related lung injury.

Original languageEnglish (US)
Article number1643
JournalDiagnostics
Volume11
Issue number9
DOIs
StatePublished - Sep 2021

Keywords

  • CC16
  • Epithelial cell
  • Inflammation
  • KL-6
  • SARS-CoV
  • SARS-CoV-2
  • Surfactant proteins

ASJC Scopus subject areas

  • Clinical Biochemistry

Fingerprint

Dive into the research topics of 'The potential of lung epithelium specific proteins as biomarkers for covid-19-associated lung injury'. Together they form a unique fingerprint.

Cite this